Skip to content

Study · Randomized controlled trial · n = 247 · 2018

2 results

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Michael Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ

ESC heart failure17 Aug 2018Cited by 39 (Europe PMC)

PMID30120812 (opens in a new tab)PMCIDPMC6300815 (opens in a new tab)DOI10.1002/ehf2.12334 (opens in a new tab)PepBankPUB-30120812
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with advanced heart failure and reduced ejection fraction, liraglutide reduced body weight more than placebo in an on-treatment post hoc analysis.

    In plain wordsIn people with advanced heart failure, liraglutide lowered body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in weight from baseline to last study visit
    Study

    n = 247

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Treatment difference in weight
    −4.1 lbs
    liraglutide vs placebo
    Percentage treatment difference
    −2.07%
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide use was associated with a significant weight reduction [liraglutide -1.00 lbs vs. placebo 2.00 lbs; treatment difference -4.10 lbs; 95% confidence interval (CI) -7.94, -0.25; P = 0.0367; percentage treatment difference -2.07%, 95% CI -3.86, -0.28; P = 0.0237].
    2 context sentences
    Summary · context
    We conducted an 'on-treatment' analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo).
    Summary · context
    The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with advanced heart failure and reduced ejection fraction, liraglutide lowered triglyceride levels more than placebo.

    In plain wordsIn people with advanced heart failure, liraglutide lowered triglycerides more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglyceride level
    Study

    n = 247

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Treatment difference in triglycerides
    −33.1 mg/dL
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference -33.1 mg/dL; 95% CI -60.7, -5.6; P = 0.019).
    2 context sentences
    Summary · context
    We conducted an 'on-treatment' analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo).
    Summary · context
    The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01800968

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Duke Universityn = 300Apr 2013 to Oct 2015

Acute Heart Failure

Trial pageClinicalTrials.govUpdated 15 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.